Human Insulin Market By Product Type (Pens, Syringes, Others), By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes) By Type of Insulin (Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, Others) By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Human Insulin Market
The human insulin market was valued at $17.1 billion in 2023 and is projected to reach $24.0 billion by 2033, growing at a CAGR of 3.4% from 2024 to 2033.
Human insulin is a synthetic mimic of the natural peptide hormone, which is synthesized in laboratory settings inside E. coli bacteria. It exists in two forms: a short-acting regular form and an intermediate-acting form known as neural protamine Hagedorn insulin. Human insulin replaces the naturally produced insulin inside the body and regulates the glucose levels in the blood.
A key driver of the human insulin market is increase in the prevalence of diabetes globally. In addition, human insulin is experiencing a surge in demand from patients and medical practitioners as compared to animal insulin owing to its high efficacy and minimal risk of allergic reactions. The latest trend in the human insulin market is the inclination of patients toward biosimilar products owing to their comparable efficacy and high cost-effectiveness.
However, the presence of other alternatives such as oral medications and non-insulin injectables, including GLP-1 receptor agonists, offers a significant competition to human insulin. Moreover, the introduction of human insulin into the market is a complex & time-consuming process due to the lengthy regulatory approval procedure at different stages, which include pre-clinical stages, clinical trials, and post-market safety monitoring. This delays the availability of the protein, thereby limiting the development of the market. On the contrary, the integration of data-driven approaches such as AI and machine learning is expected to speed up production efficiency by optimizing the production parameters and predicting product yields.
Segment Review
The human insulin market is segmented into product type, indication, type of insulin, distribution channel, and region. On the basis of product type, the market is divided into pens, syringes, and others. As per indication, it is classified into type 1 diabetes, type 2 diabetes, and gestational diabetes. Depending on type of insulin, it is categorized into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and others. According to distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product type, the pens segment dominated the market in 2023.
As per indication, the type-1 diabetes segment acquired high stakes in the market in 2023.
Depending on type of insulin, the rapid-acting insulin segment garnered a high market share in 2023.
According to distribution channel, the drug stores & retail pharmacies segment was the highest shareholder in 2023.
Region wise, North America was the highest revenue generator in 2023.
Competition Analysis
The major players operating in the global human insulin market include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer, Biocon, Wockhardt, MannKind Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd., Medtronic, and Lupin. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Key Market Segments
By Product Type
Pens
Syringes
Others
By Indication
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
By Type Of Insulin
Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Eli Lilly and Company
Sanofi
Novo Nordisk A/S
Pfizer
Biocon
Wockhardt
MannKind Corporation
Tonghua Dongbao Pharmaceutical Co., Ltd.
Medtronic
Lupin
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
- 3.5.1. Drivers
- 3.5.2. Restraints
- 3.5.3. Opportunities
- CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product Type
- 4.2. Pens
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Syringes
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Others
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Indication
- 5.2. Type 1 Diabetes
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Type 2 Diabetes
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Gestational Diabetes
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
- CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Type Of Insulin
- 6.2. Rapid-acting Insulin
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Short-acting Insulin
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Intermediate-acting Insulin
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- 6.5. Others
- 6.5.1. Key Market Trends, Growth Factors and Opportunities
- 6.5.2. Market Size and Forecast, By Region
- 6.5.3. Market Share Analysis, By Country
- CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Distribution Channel
- 7.2. Hospital Pharmacies
- 7.2.1. Key Market Trends, Growth Factors and Opportunities
- 7.2.2. Market Size and Forecast, By Region
- 7.2.3. Market Share Analysis, By Country
- 7.3. Drug Stores And Retail Pharmacies
- 7.3.1. Key Market Trends, Growth Factors and Opportunities
- 7.3.2. Market Size and Forecast, By Region
- 7.3.3. Market Share Analysis, By Country
- 7.4. Online Providers
- 7.4.1. Key Market Trends, Growth Factors and Opportunities
- 7.4.2. Market Size and Forecast, By Region
- 7.4.3. Market Share Analysis, By Country
- CHAPTER 8: HUMAN INSULIN MARKET, BY REGION
- 8.1. Market Overview
- 8.1.1 Market Size and Forecast, By Region
- 8.2. North America
- 8.2.1. Key Market Trends and Opportunities
- 8.2.2. Market Size and Forecast, By Product Type
- 8.2.3. Market Size and Forecast, By Indication
- 8.2.4. Market Size and Forecast, By Type Of Insulin
- 8.2.5. Market Size and Forecast, By Distribution Channel
- 8.2.6. Market Size and Forecast, By Country
- 8.2.7. U.S. Human Insulin Market
- 8.2.7.1. Market Size and Forecast, By Product Type
- 8.2.7.2. Market Size and Forecast, By Indication
- 8.2.7.3. Market Size and Forecast, By Type Of Insulin
- 8.2.7.4. Market Size and Forecast, By Distribution Channel
- 8.2.8. Canada Human Insulin Market
- 8.2.8.1. Market Size and Forecast, By Product Type
- 8.2.8.2. Market Size and Forecast, By Indication
- 8.2.8.3. Market Size and Forecast, By Type Of Insulin
- 8.2.8.4. Market Size and Forecast, By Distribution Channel
- 8.2.9. Mexico Human Insulin Market
- 8.2.9.1. Market Size and Forecast, By Product Type
- 8.2.9.2. Market Size and Forecast, By Indication
- 8.2.9.3. Market Size and Forecast, By Type Of Insulin
- 8.2.9.4. Market Size and Forecast, By Distribution Channel
- 8.3. Europe
- 8.3.1. Key Market Trends and Opportunities
- 8.3.2. Market Size and Forecast, By Product Type
- 8.3.3. Market Size and Forecast, By Indication
- 8.3.4. Market Size and Forecast, By Type Of Insulin
- 8.3.5. Market Size and Forecast, By Distribution Channel
- 8.3.6. Market Size and Forecast, By Country
- 8.3.7. Germany Human Insulin Market
- 8.3.7.1. Market Size and Forecast, By Product Type
- 8.3.7.2. Market Size and Forecast, By Indication
- 8.3.7.3. Market Size and Forecast, By Type Of Insulin
- 8.3.7.4. Market Size and Forecast, By Distribution Channel
- 8.3.8. France Human Insulin Market
- 8.3.8.1. Market Size and Forecast, By Product Type
- 8.3.8.2. Market Size and Forecast, By Indication
- 8.3.8.3. Market Size and Forecast, By Type Of Insulin
- 8.3.8.4. Market Size and Forecast, By Distribution Channel
- 8.3.9. UK Human Insulin Market
- 8.3.9.1. Market Size and Forecast, By Product Type
- 8.3.9.2. Market Size and Forecast, By Indication
- 8.3.9.3. Market Size and Forecast, By Type Of Insulin
- 8.3.9.4. Market Size and Forecast, By Distribution Channel
- 8.3.10. Italy Human Insulin Market
- 8.3.10.1. Market Size and Forecast, By Product Type
- 8.3.10.2. Market Size and Forecast, By Indication
- 8.3.10.3. Market Size and Forecast, By Type Of Insulin
- 8.3.10.4. Market Size and Forecast, By Distribution Channel
- 8.3.11. Spain Human Insulin Market
- 8.3.11.1. Market Size and Forecast, By Product Type
- 8.3.11.2. Market Size and Forecast, By Indication
- 8.3.11.3. Market Size and Forecast, By Type Of Insulin
- 8.3.11.4. Market Size and Forecast, By Distribution Channel
- 8.3.12. Rest Of Europe Human Insulin Market
- 8.3.12.1. Market Size and Forecast, By Product Type
- 8.3.12.2. Market Size and Forecast, By Indication
- 8.3.12.3. Market Size and Forecast, By Type Of Insulin
- 8.3.12.4. Market Size and Forecast, By Distribution Channel
- 8.4. Asia-Pacific
- 8.4.1. Key Market Trends and Opportunities
- 8.4.2. Market Size and Forecast, By Product Type
- 8.4.3. Market Size and Forecast, By Indication
- 8.4.4. Market Size and Forecast, By Type Of Insulin
- 8.4.5. Market Size and Forecast, By Distribution Channel
- 8.4.6. Market Size and Forecast, By Country
- 8.4.7. Japan Human Insulin Market
- 8.4.7.1. Market Size and Forecast, By Product Type
- 8.4.7.2. Market Size and Forecast, By Indication
- 8.4.7.3. Market Size and Forecast, By Type Of Insulin
- 8.4.7.4. Market Size and Forecast, By Distribution Channel
- 8.4.8. China Human Insulin Market
- 8.4.8.1. Market Size and Forecast, By Product Type
- 8.4.8.2. Market Size and Forecast, By Indication
- 8.4.8.3. Market Size and Forecast, By Type Of Insulin
- 8.4.8.4. Market Size and Forecast, By Distribution Channel
- 8.4.9. India Human Insulin Market
- 8.4.9.1. Market Size and Forecast, By Product Type
- 8.4.9.2. Market Size and Forecast, By Indication
- 8.4.9.3. Market Size and Forecast, By Type Of Insulin
- 8.4.9.4. Market Size and Forecast, By Distribution Channel
- 8.4.10. Australia Human Insulin Market
- 8.4.10.1. Market Size and Forecast, By Product Type
- 8.4.10.2. Market Size and Forecast, By Indication
- 8.4.10.3. Market Size and Forecast, By Type Of Insulin
- 8.4.10.4. Market Size and Forecast, By Distribution Channel
- 8.4.11. South Korea Human Insulin Market
- 8.4.11.1. Market Size and Forecast, By Product Type
- 8.4.11.2. Market Size and Forecast, By Indication
- 8.4.11.3. Market Size and Forecast, By Type Of Insulin
- 8.4.11.4. Market Size and Forecast, By Distribution Channel
- 8.4.12. Rest of Asia-Pacific Human Insulin Market
- 8.4.12.1. Market Size and Forecast, By Product Type
- 8.4.12.2. Market Size and Forecast, By Indication
- 8.4.12.3. Market Size and Forecast, By Type Of Insulin
- 8.4.12.4. Market Size and Forecast, By Distribution Channel
- 8.5. LAMEA
- 8.5.1. Key Market Trends and Opportunities
- 8.5.2. Market Size and Forecast, By Product Type
- 8.5.3. Market Size and Forecast, By Indication
- 8.5.4. Market Size and Forecast, By Type Of Insulin
- 8.5.5. Market Size and Forecast, By Distribution Channel
- 8.5.6. Market Size and Forecast, By Country
- 8.5.7. Brazil Human Insulin Market
- 8.5.7.1. Market Size and Forecast, By Product Type
- 8.5.7.2. Market Size and Forecast, By Indication
- 8.5.7.3. Market Size and Forecast, By Type Of Insulin
- 8.5.7.4. Market Size and Forecast, By Distribution Channel
- 8.5.8. Saudi Arabia Human Insulin Market
- 8.5.8.1. Market Size and Forecast, By Product Type
- 8.5.8.2. Market Size and Forecast, By Indication
- 8.5.8.3. Market Size and Forecast, By Type Of Insulin
- 8.5.8.4. Market Size and Forecast, By Distribution Channel
- 8.5.9. South Africa Human Insulin Market
- 8.5.9.1. Market Size and Forecast, By Product Type
- 8.5.9.2. Market Size and Forecast, By Indication
- 8.5.9.3. Market Size and Forecast, By Type Of Insulin
- 8.5.9.4. Market Size and Forecast, By Distribution Channel
- 8.5.10. Rest of LAMEA Human Insulin Market
- 8.5.10.1. Market Size and Forecast, By Product Type
- 8.5.10.2. Market Size and Forecast, By Indication
- 8.5.10.3. Market Size and Forecast, By Type Of Insulin
- 8.5.10.4. Market Size and Forecast, By Distribution Channel
- CHAPTER 9: COMPETITIVE LANDSCAPE
- 9.1. Introduction
- 9.2. Top Winning Strategies
- 9.3. Product Mapping Of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top Player Positioning, 2023
- CHAPTER 10: COMPANY PROFILES
- 10.1. Eli Lilly And Company
- 10.1.1. Company Overview
- 10.1.2. Key Executives
- 10.1.3. Company Snapshot
- 10.1.4. Operating Business Segments
- 10.1.5. Product Portfolio
- 10.1.6. Business Performance
- 10.1.7. Key Strategic Moves and Developments
- 10.2. Sanofi
- 10.2.1. Company Overview
- 10.2.2. Key Executives
- 10.2.3. Company Snapshot
- 10.2.4. Operating Business Segments
- 10.2.5. Product Portfolio
- 10.2.6. Business Performance
- 10.2.7. Key Strategic Moves and Developments
- 10.3. Novo Nordisk A/S
- 10.3.1. Company Overview
- 10.3.2. Key Executives
- 10.3.3. Company Snapshot
- 10.3.4. Operating Business Segments
- 10.3.5. Product Portfolio
- 10.3.6. Business Performance
- 10.3.7. Key Strategic Moves and Developments
- 10.4. Pfizer
- 10.4.1. Company Overview
- 10.4.2. Key Executives
- 10.4.3. Company Snapshot
- 10.4.4. Operating Business Segments
- 10.4.5. Product Portfolio
- 10.4.6. Business Performance
- 10.4.7. Key Strategic Moves and Developments
- 10.5. Biocon
- 10.5.1. Company Overview
- 10.5.2. Key Executives
- 10.5.3. Company Snapshot
- 10.5.4. Operating Business Segments
- 10.5.5. Product Portfolio
- 10.5.6. Business Performance
- 10.5.7. Key Strategic Moves and Developments
- 10.6. Wockhardt
- 10.6.1. Company Overview
- 10.6.2. Key Executives
- 10.6.3. Company Snapshot
- 10.6.4. Operating Business Segments
- 10.6.5. Product Portfolio
- 10.6.6. Business Performance
- 10.6.7. Key Strategic Moves and Developments
- 10.7. MannKind Corporation
- 10.7.1. Company Overview
- 10.7.2. Key Executives
- 10.7.3. Company Snapshot
- 10.7.4. Operating Business Segments
- 10.7.5. Product Portfolio
- 10.7.6. Business Performance
- 10.7.7. Key Strategic Moves and Developments
- 10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
- 10.8.1. Company Overview
- 10.8.2. Key Executives
- 10.8.3. Company Snapshot
- 10.8.4. Operating Business Segments
- 10.8.5. Product Portfolio
- 10.8.6. Business Performance
- 10.8.7. Key Strategic Moves and Developments
- 10.9. Medtronic
- 10.9.1. Company Overview
- 10.9.2. Key Executives
- 10.9.3. Company Snapshot
- 10.9.4. Operating Business Segments
- 10.9.5. Product Portfolio
- 10.9.6. Business Performance
- 10.9.7. Key Strategic Moves and Developments
- 10.10. Lupin
- 10.10.1. Company Overview
- 10.10.2. Key Executives
- 10.10.3. Company Snapshot
- 10.10.4. Operating Business Segments
- 10.10.5. Product Portfolio
- 10.10.6. Business Performance
- 10.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 2. HUMAN INSULIN MARKET FOR PENS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. HUMAN INSULIN MARKET FOR SYRINGES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. HUMAN INSULIN MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. GLOBAL HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 6. HUMAN INSULIN MARKET FOR TYPE 1 DIABETES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. HUMAN INSULIN MARKET FOR TYPE 2 DIABETES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. HUMAN INSULIN MARKET FOR GESTATIONAL DIABETES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 9. GLOBAL HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 10. HUMAN INSULIN MARKET FOR RAPID-ACTING INSULIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. HUMAN INSULIN MARKET FOR SHORT-ACTING INSULIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. HUMAN INSULIN MARKET FOR INTERMEDIATE-ACTING INSULIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. HUMAN INSULIN MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 14. GLOBAL HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 15. HUMAN INSULIN MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 16. HUMAN INSULIN MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 17. HUMAN INSULIN MARKET FOR ONLINE PROVIDERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 18. HUMAN INSULIN MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 19. NORTH AMERICA HUMAN INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 20. NORTH AMERICA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 21. NORTH AMERICA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 22. NORTH AMERICA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 23. NORTH AMERICA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 24. U.S. HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 25. U.S. HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 26. U.S. HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 27. U.S. HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 28. CANADA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 29. CANADA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 30. CANADA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 31. CANADA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 32. MEXICO HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 33. MEXICO HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 34. MEXICO HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 35. MEXICO HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 36. EUROPE HUMAN INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 37. EUROPE HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 38. EUROPE HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 39. EUROPE HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 40. EUROPE HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 41. GERMANY HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 42. GERMANY HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 43. GERMANY HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 44. GERMANY HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 45. FRANCE HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 46. FRANCE HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 47. FRANCE HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 48. FRANCE HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 49. UK HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 50. UK HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 51. UK HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 52. UK HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 53. ITALY HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 54. ITALY HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 55. ITALY HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 56. ITALY HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 57. SPAIN HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 58. SPAIN HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 59. SPAIN HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 60. SPAIN HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 61. REST OF EUROPE HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 62. REST OF EUROPE HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 63. REST OF EUROPE HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 64. REST OF EUROPE HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 65. ASIA-PACIFIC HUMAN INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 66. ASIA-PACIFIC HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 67. ASIA-PACIFIC HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 68. ASIA-PACIFIC HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 69. ASIA-PACIFIC HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 70. JAPAN HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 71. JAPAN HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 72. JAPAN HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 73. JAPAN HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 74. CHINA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 75. CHINA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 76. CHINA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 77. CHINA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 78. INDIA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 79. INDIA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 80. INDIA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 81. INDIA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 82. AUSTRALIA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 83. AUSTRALIA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 84. AUSTRALIA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 85. AUSTRALIA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 86. SOUTH KOREA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 87. SOUTH KOREA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 88. SOUTH KOREA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 89. SOUTH KOREA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 90. REST OF ASIA-PACIFIC HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 91. REST OF ASIA-PACIFIC HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 92. REST OF ASIA-PACIFIC HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 93. REST OF ASIA-PACIFIC HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 94. LAMEA HUMAN INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 95. LAMEA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 96. LAMEA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 97. LAMEA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 98. LAMEA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 99. BRAZIL HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 100. BRAZIL HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 101. BRAZIL HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 102. BRAZIL HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 103. SAUDI ARABIA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 104. SAUDI ARABIA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 105. SAUDI ARABIA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 106. SAUDI ARABIA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 107. SOUTH AFRICA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 108. SOUTH AFRICA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 109. SOUTH AFRICA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 110. SOUTH AFRICA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 111. REST OF LAMEA HUMAN INSULIN, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
- TABLE 112. REST OF LAMEA HUMAN INSULIN, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 113. REST OF LAMEA HUMAN INSULIN, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
- TABLE 114. REST OF LAMEA HUMAN INSULIN, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 115. ELI LILLY AND COMPANY: KEY EXECUTIVES
- TABLE 116. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 117. ELI LILLY AND COMPANY: OPERATING SEGMENTS
- TABLE 118. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
- TABLE 119. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 120. SANOFI: KEY EXECUTIVES
- TABLE 121. SANOFI: COMPANY SNAPSHOT
- TABLE 122. SANOFI: OPERATING SEGMENTS
- TABLE 123. SANOFI: PRODUCT PORTFOLIO
- TABLE 124. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 125. NOVO NORDISK A/S: KEY EXECUTIVES
- TABLE 126. NOVO NORDISK A/S: COMPANY SNAPSHOT
- TABLE 127. NOVO NORDISK A/S: OPERATING SEGMENTS
- TABLE 128. NOVO NORDISK A/S: PRODUCT PORTFOLIO
- TABLE 129. NOVO NORDISK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 130. PFIZER: KEY EXECUTIVES
- TABLE 131. PFIZER: COMPANY SNAPSHOT
- TABLE 132. PFIZER: OPERATING SEGMENTS
- TABLE 133. PFIZER: PRODUCT PORTFOLIO
- TABLE 134. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 135. BIOCON: KEY EXECUTIVES
- TABLE 136. BIOCON: COMPANY SNAPSHOT
- TABLE 137. BIOCON: OPERATING SEGMENTS
- TABLE 138. BIOCON: PRODUCT PORTFOLIO
- TABLE 139. BIOCON: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 140. WOCKHARDT: KEY EXECUTIVES
- TABLE 141. WOCKHARDT: COMPANY SNAPSHOT
- TABLE 142. WOCKHARDT: OPERATING SEGMENTS
- TABLE 143. WOCKHARDT: PRODUCT PORTFOLIO
- TABLE 144. WOCKHARDT: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 145. MANNKIND CORPORATION: KEY EXECUTIVES
- TABLE 146. MANNKIND CORPORATION: COMPANY SNAPSHOT
- TABLE 147. MANNKIND CORPORATION: OPERATING SEGMENTS
- TABLE 148. MANNKIND CORPORATION: PRODUCT PORTFOLIO
- TABLE 149. MANNKIND CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 150. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
- TABLE 151. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
- TABLE 152. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
- TABLE 153. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
- TABLE 154. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 155. MEDTRONIC: KEY EXECUTIVES
- TABLE 156. MEDTRONIC: COMPANY SNAPSHOT
- TABLE 157. MEDTRONIC: OPERATING SEGMENTS
- TABLE 158. MEDTRONIC: PRODUCT PORTFOLIO
- TABLE 159. MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 160. LUPIN: KEY EXECUTIVES
- TABLE 161. LUPIN: COMPANY SNAPSHOT
- TABLE 162. LUPIN: OPERATING SEGMENTS
- TABLE 163. LUPIN: PRODUCT PORTFOLIO
- TABLE 164. LUPIN: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL HUMAN INSULIN MARKET SEGMENTATION
- FIGURE 2. GLOBAL HUMAN INSULIN MARKET
- FIGURE 3. SEGMENTATION HUMAN INSULIN MARKET
- FIGURE 4. TOP INVESTMENT POCKET IN HUMAN INSULIN MARKET
- FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 8. LOW THREAT OF SUBSTITUTION
- FIGURE 9. HIGH COMPETITIVE RIVALRY
- FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHUMAN INSULIN MARKET
- FIGURE 11. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY PRODUCT TYPE
- FIGURE 12. HUMAN INSULIN MARKET FOR PENS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. HUMAN INSULIN MARKET FOR SYRINGES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. HUMAN INSULIN MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 15. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY INDICATION
- FIGURE 16. HUMAN INSULIN MARKET FOR TYPE 1 DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. HUMAN INSULIN MARKET FOR TYPE 2 DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 18. HUMAN INSULIN MARKET FOR GESTATIONAL DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 19. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY TYPE OF INSULIN
- FIGURE 20. HUMAN INSULIN MARKET FOR RAPID-ACTING INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 21. HUMAN INSULIN MARKET FOR SHORT-ACTING INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 22. HUMAN INSULIN MARKET FOR INTERMEDIATE-ACTING INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 23. HUMAN INSULIN MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 24. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
- FIGURE 25. HUMAN INSULIN MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 26. HUMAN INSULIN MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 27. HUMAN INSULIN MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 28. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 29. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 30. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 31. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 32. COMPETITIVE DASHBOARD
- FIGURE 33. COMPETITIVE HEATMAP: HUMAN INSULIN MARKET
- FIGURE 34. TOP PLAYER POSITIONING, 2023
- FIGURE 35. ELI LILLY AND COMPANY: NET SALES, 2021-2023 ($BILLION)
- FIGURE 36. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 37. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 38. SANOFI: NET SALES, 2021-2023 ($BILLION)
- FIGURE 39. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 40. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 41. NOVO NORDISK A/S: NET SALES, 2021-2023 ($BILLION)
- FIGURE 42. NOVO NORDISK A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 43. NOVO NORDISK A/S: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 44. PFIZER: NET SALES, 2021-2023 ($BILLION)
- FIGURE 45. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 46. PFIZER: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 47. BIOCON: NET SALES, 2021-2023 ($BILLION)
- FIGURE 48. BIOCON: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 49. BIOCON: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 50. WOCKHARDT: NET SALES, 2021-2023 ($BILLION)
- FIGURE 51. WOCKHARDT: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 52. WOCKHARDT: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 53. MANNKIND CORPORATION: NET SALES, 2021-2023 ($BILLION)
- FIGURE 54. MANNKIND CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 55. MANNKIND CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 56. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 57. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 58. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 59. MEDTRONIC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 60. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 61. MEDTRONIC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 62. LUPIN: NET SALES, 2021-2023 ($BILLION)
- FIGURE 63. LUPIN: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 64. LUPIN: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook